PDPN and neoplasm: A mouse-human chimeric anti-PDPN mAb, named chLpMab-7 (human IgG1, kappa), which recognizes the PLD domain, did not show neutralization activity for CLEC-2 binding but suppressed tumor growth and hematogenous metastasis to the lung, indicating that ADCC/CDC activities are essential for targeting PDPN-positive tumors [17].